Medicus Pharma Reports Breakthrough Skin Cancer Results and Expands Oncology Pipeline

Medicus Pharma (NASDAQ: MDCX) is advancing innovative therapies with promising Phase 2 results in basal cell carcinoma, where up to 3 out of 4 patients avoided surgery using its microneedle-based treatment platform. The technology offers a minimally invasive alternative to traditional procedures, with potential benefits including no scarring, lower cost, and improved patient experience. Beyond dermatologic oncology, Medicus is expanding its pipeline with Teverelix, a next-generation therapy targeting advanced prostate cancer and cardiovascular risk, along with additional studies in acute urinary retention. With multiple clinical catalysts ahead and ongoing FDA engagement, the company is positioning itself for continued growth in the biotech sector. #MedicusPharma #MDCX #Biotech #SkinCancer #BasalCellCarcinoma #ClinicalTrials #Oncology #ProstateCancer #DrugDevelopment #HealthcareInnovation #MedicalResearch #Pharmaceuticals #BiotechInvesting #LifeSciences #NewsOut